-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 29, 2022, the "HCC International Frontier and Normative Summit Forum" was successfully held in the form of online and offline jointly hosted by the Oncology and Hepatology Professional Committee of the Chinese Anti-Cancer Association, the Microbiology Research Center of the University of New South Wales in Australia, the Cordeliers Research Center of the University of Descartes in Paris, France, co-organized by the Liver Cancer Prevention and Treatment Research Center of Tianjin Medical University Cancer Hospital, and
undertaken by the Department of Hepatobiliary Oncology of Tianjin Medical University Cancer Hospital 。 Professor Lu Wei of Tianjin Medical University Cancer Hospital, Professor Jessica Zucman-rossi of the Cordelier Research Center of Descartes University in Paris, France, and Professor Emad EI-Omar, Microbiology Research Center, University of New South Wales, Australia co-chaired
the conference.
Conference highlights
This conference focused on the international frontier progress, standardized management and clinical practice of HCC, and invited experts and scholars from France, Australia and other countries and China to conduct academic discussions on the early mechanism of liver cancer, microorganisms and liver cancer, management of portal hypertension, practice and exploration of T+A scheme, TALENTOP cases and MDT
.
The successful convening of the conference will greatly promote the academic exchanges and scientific research cooperation between basic and clinical experts in the participating countries and regions, and then improve the diagnosis and treatment level
of hepatocellular carcinoma.
Great content
In his opening speech, Professor Lu Wei said that the HCC International Frontier and Normative Summit Forum aims to build a bridge and platform to promote better academic exchanges and cooperation
among international HCC experts.
Here, HCC experts from different countries and regions will exchange cutting-edge progress in the field of HCC and exchange ideas
on related research topics.
It is hoped that this summit can help further improve the level of basic and clinical research on liver cancer, and promote the exchange and collaboration
of multidisciplinary diagnosis and treatment research of liver cancer at home and abroad.
Professor Jessica Zucman-rossi thanked the invited participants and said that the successful holding of this summit will strongly promote the scientific research and academic cooperation between China and France in the field of HCC, and looks forward to more cooperation
in the future.
Professor Emad EI-Omar is very pleased to join the international HCC experts and looks forward to today's exchange and learning to help improve the diagnosis and treatment of HCC worldwide
.
The conference is divided into three chapters
: "International Frontier", "Normative Leadership" and "Clinical Practice".
The highlights are organized as follows:
Chapter 1: International Frontier
Professor Jessica Zucman-rossi, in her sharing entitled "Early Mechanism of Liver Cancer Genesis", pointed out that the somatic cytogenetics of HCC is highly correlated with environmental exposure and HCC risk factors, suggesting the importance of
prevention.
The genome of HCC is also related to the patient's own condition and tumor phenotype, suggesting that prognostic markers and new targets are needed clinically, and TERT and other very effective new therapeutic targets
.
In this session, Professor Lu Wei served as the chairman, Professor Zhang Ningning of Tianjin Medical University Cancer Hospital and Professor Duan Feng of the First Medical Center of the Chinese People's Liberation Army General Hospital commented and exchanged
views as panelists.
Professor Amany Zekry of St.
George's Hospital, University of New South Wales, Australia, pointed out in the keynote report "Microbiota and Liver Cancer" that immune escape is one of the mechanisms of liver cancer, and immunotherapy is the main therapy
for advanced HCC.
Microbiome measures taken to understand the human gut and tumor microenvironment can prevent the occurrence or recurrence of HCC after surgical resection, treat complications of cirrhosis, and improve immunotherapy outcomes
.
In this session, Professor Zhang Yamin of Tianjin First Central Hospital served as the host guest, Professor Gong Lan of the Microbiology Research Center of the University of New South Wales in Australia and Professor Tian Weijun of the General Hospital of Tianjin Medical University participated in the comments and discussions
.
Professor Manon Allaire of Hôpital Universitaire Pitié-Salpêtrière Hospital in France pointed out in the theme report "Management of portal hypertension in HCC treatment" that HCC is closely related to portal hypertension, and the coexistence of HCC and portal hypertension in the same patient is associated with
suboptimal management of HCC and increased mortality from variceal bleeding.
Patients with HCC who are difficult to adopt Baveno criteria should be the preferred endoscopy for varicose vein screening
.
Data on the efficacy of NSBB (particularly carvedilol) in HCC patients and portal vein invasion are still lacking
.
Durvalumab/CTLA-4 inhibitor tremelimumab may be the new treatment
for patients with advanced HCC with a history of bleeding.
Professor Ren Xiubao of Tianjin Medical University Cancer Hospital was the host of this session, Professor Xu Liang of Tianjin Second People's Hospital and Professor Yu Haipeng of Tianjin Medical University Cancer Hospital participated in the discussion
.
Chapter 2: Normative Guidance
Professor Cui Zilin of Tianjin First Central Hospital reviewed the initial exploration of atezolizumab and bevacizumab in the theme report "Past, present and future of systematic treatment of advanced liver cancer", sorted out the course of atezolizumab + bevacizumab (T+A protocol) in the collaborative fight against HCC, and shared a series of exploratory research new progress, describing the future of atezolizumab + bevacizumab, including MO42541, TALENTACE, IMbrave 050, ABC-HCC and TALENTOP studies, among others
.
Professor Zhao Yue of Qinhuangdao Cancer Hospital commented and discussed
.
Professor Liu Quanyan of Tianjin Medical University General Hospital discussed neoadjuvant therapy, conversion therapy and postoperative adjuvant therapy
for liver cancer from the perspective of surgical experts in his sharing entitled "Target Immunity Joint Original Chinese Practice".
The T+A program opens a new chapter in the treatment of advanced liver cancer, which is widely used in the real world, and provides new evidence and new opportunities
for the clinical practice and exploration of advanced liver cancer.
The efficacy and safety of T+A regimen in IMbrave150 study are reproducible in routine clinical practice, and the clinical benefits of T+A regimen in different scenarios are also being explored, such as patients with poor liver function, follow-up options for first-line T+A therapy, and combination with local therapy
.
In addition, a number of clinical studies based on the T+A regimen are being carried out in China, providing richer clinical evidence for the use of T+A regimen in Chinese liver cancer patients and achieving more survival benefits
.
Professor Wang Yusheng of Shanxi Cancer Hospital and Professor Chen Kai of Tianjin Fourth Central Hospital participated in the discussion
.
Chapter 3: Clinical Practice
This chapter is presided over
by Professor Xu Jun of the First Hospital of Shanxi Medical University.
Professor Zhang Wei of Tianjin Medical University Cancer Hospital shared a case of liver cancer conversion therapy in the TALENTOP study, from stage IIIa unresectable tumor, after 3 cycles of T+A regimen treatment, imaging PR, tumor marker level decreased significantly, recovered smoothly after resection, waiting for subsequent T+A regimen treatment
.
Subsequently, Professor Si Tongguo and Professor Wu Qiang of Tianjin Medical University Cancer Hospital, Professor Li Wenxin of Inner Mongolia Autonomous Region People's Hospital and Professor Liang Jing of Tianjin Medical University Cancer Hospital participated in the MDT discussion session
.
Professor Ren Xiubao of Tianjin Medical University Cancer Hospital pointed out in the summary of the meeting that this summit invited well-known liver cancer experts at home and abroad to carry out in-depth international cutting-edge academic exchanges on liver cancer, demonstrated the new progress in the field of basic and clinical research of liver cancer, and believed that it will promote the close integration of production, education and research, establish a multidisciplinary joint research cooperation platform for liver cancer, and contribute to
promoting the improvement of liver cancer diagnosis and treatment technology and overall research level.
